36405505|t|An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use.
36405505|a|There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 decades of use, key aspects have been well studied, including population pharmacokinetics, CYP interactions and various clinical and economic outcomes. However, there are still unknowns with these medications. Issues including adherence, transition from oral antipsychotics, renal dosing, pharmacogenomics, and managing missed doses will be addressed in the context of 4 patient cases.
36405505	234	246	aripiprazole	Chemical	MESH:D000068180
36405505	252	262	olanzapine	Chemical	MESH:D000077152
36405505	268	280	paliperidone	Chemical	MESH:D000068882
36405505	290	301	risperidone	Chemical	MESH:D018967
36405505	394	401	patient	Species	9606
36405505	797	804	patient	Species	9606

